Semaglutide Side Effects: What to Expect in Chattanooga

I bring up side effects on the first visit, before a patient in Chattanooga or Signal Mountain has even decided to start semaglutide. Not because I have to. Because most people quit a GLP-1 in the first three weeks for a reason nobody warned them about, and the honest version of that conversation is the whole difference between someone who stops at week 3 and someone who’s still here at week 68. I’m Dr. Paul Miranda, board-certified, and I review every chart at Summit Metabolic Health myself. Here’s what semaglutide actually does to your body, by the numbers, and how to get through the part that makes people quit.

Semaglutide is a GLP-1 receptor agonist. It mimics a gut hormone your body already makes after eating. Three things happen when it binds:

Gastric emptying slows down. Food sits in your stomach longer, which is part of why you feel full faster — and part of why you feel nauseated if you eat too much, too fast, or something too fatty.

Your hypothalamus gets a satiety signal it wasn’t getting before. This is the appetite suppression patients notice. It’s not willpower. It’s the brain being told you’ve had enough.

Insulin release and glucagon suppression become glucose-dependent — the drug ramps them up when your blood sugar is high and backs off when it isn’t, which is why hypoglycemia risk on semaglutide alone is low.

That first mechanism — slowed gastric emptying — is the one that matters most for this post. It’s directly responsible for the nausea and GI symptoms that show up across every semaglutide trial. This isn’t a flaw in the drug. It’s the mechanism working. The side effect and the appetite suppression come from the same signal.

The STEP 1 trial (Wilding et al., NEJM, 2021) is the reference point for semaglutide in obesity. At 68 weeks, patients on semaglutide lost a mean of 14.9% of body weight, versus 2.6% on placebo. That’s the upside everyone quotes. The tradeoff patients actually feel is in the same dataset, and it’s GI-predominant: nausea, diarrhea, constipation, and vomiting were the most commonly reported adverse events, concentrated in the dose-escalation weeks.

Two things in that trial matter more than the headline percentages:

Most GI side effects were mild to moderate and transient — they eased as the body adjusted to each new dose level, and I walk through the practical fixes for that stretch (fiber, hydration, meal size) in a doctor’s guide to the common GLP-1 side effects. And weight loss did not require feeling sick. Mediation analyses across the STEP program show the weight effect is largely independent of the GI symptoms, meaning the drug isn’t working because it makes you nauseated. Managing the side effect aggressively doesn’t blunt the result.

The same GI-predominant pattern shows up across the SURPASS trials for tirzepatide, which shares the slowed-gastric-emptying mechanism. It’s a class effect, not a one-drug quirk — which is exactly why the dosing schedule, not the molecule, is where most of the difference gets made. I go deeper on that mechanism in why the GLP-1 dose escalation schedule exists in the first place — it’s the piece almost nobody explains before handing you a prescription.

Semaglutide carries a boxed warning for thyroid C-cell tumors, based on rodent data, and is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. That’s a screening question, not a footnote — it has to happen before a prescription is written, not after.

But the honest side-effect conversation isn’t complete without the other half of the data: the cardiovascular and renal outcomes trials, which exist precisely because a drug this widely prescribed needs its risk looked at over the long term, not just at 68 weeks.

SELECT (Lincoln et al., 2023) followed semaglutide in patients with established cardiovascular disease and found a 20% reduction in major adverse cardiovascular events — heart attack, stroke, cardiovascular death — compared to placebo. FLOW (Perkovic et al., 2024) found a 24% reduction in major kidney-disease events in patients with type 2 diabetes and chronic kidney disease. Neither trial makes the nausea disappear. Both change the calculation you’re actually making: this medication’s side-effect profile is being weighed against real, trial-measured protection, in a risk/benefit conversation that belongs with a physician — not a symptom you report into an app and hope someone reads.

Here’s the pattern I see over and over: a patient starts on a fixed titration schedule set by an app, not a person. The schedule doesn’t know they’re a small-framed 58-year-old or a 220-pound former athlete. It escalates on a calendar because the calendar says four weeks are up, not because the patient is ready. They get hit with nausea hard enough to stop eating, stop drinking fluids, and show up dehydrated — sometimes in an ER. I’ve worked emergency medicine long enough to see this exact scenario more than once. It’s avoidable.

Dose titration is the single highest-leverage decision in GLP-1 therapy, and it has to be individualized: how a patient tolerates each step, not how fast the manufacturer’s own titration guide allows — the same reason some patients feel hungrier at certain dose steps than others instead of steadily less hungry throughout. That means someone reachable when a patient calls at day 10 and says the nausea is bad — not a support ticket, not a chatbot, a physician who can hold the dose, adjust the pace, or troubleshoot the actual symptom. A patient who’s managed through week 3 is a patient who’s still here at week 68. A patient who’s told to push through, or worse, ignored, quits — and then tells everyone semaglutide “didn’t work for them,” when the truth is nobody managed the dose.

Ro, Hims/Hers, Henry Meds, and Found built businesses on making a GLP-1 prescription available in a few clicks. What none of them offer is a named prescriber who knows your chart and adjusts your dose in real time. Side effects get reported into an app, into a queue, and answered — if they’re answered — by whoever’s on shift. There’s no relationship, and titration decisions get made by a protocol, not a person watching how you’re actually doing.

At Summit, I review every chart myself. Dosing is a flat, descending model — no lock-in, no cancellation fee — built specifically so a side effect gets managed with a dose adjustment, not a lecture to push through it or a subscription you’re stuck paying while you quit. If nausea shows up at a dose step, we hold it, or step back, until your body catches up. That’s not a slower path to the same result; it’s the reason people finish the program instead of stopping at week 3. And for patients who want an in-person option, Chattanooga has one — something none of the DTC platforms above can offer at any price.

Weeks 1–4 (starting dose): Mild nausea, especially after eating too much or too fast, is common and expected. Smaller meals, stopping when you feel 80% full, and avoiding high-fat food usually settle it within days. Call if you can’t keep fluids down for more than 24 hours.

Weeks 4–8 (first dose increase): GI symptoms often reappear briefly at each step-up — this is the pattern the STEP trials describe. Nausea, softer stools, or constipation are typical and usually transient. Call if constipation persists beyond a week despite fiber and fluids, or if vomiting recurs more than once a day.

Weeks 8–20 (ongoing escalation): Symptoms generally quiet down between dose increases as your body adjusts. New or worsening abdominal pain — especially severe, persistent pain radiating to the back — is not typical and needs a same-day call; it’s the pattern associated with pancreatitis, and it gets evaluated, not waited out.

Any point: Signs of an allergic reaction (facial swelling, difficulty breathing, hives), a new neck lump or persistent hoarseness, or symptoms of a rapid heartbeat that don’t resolve — call immediately. These are rare, but they’re the reason a physician screens you before the first injection and stays reachable after it.

Semaglutide’s side effects are real, and the honest version of this conversation is that most people feel them at some point. The trial data — STEP 1’s discontinuation rate, SELECT’s cardiovascular numbers, FLOW’s renal findings — show a drug worth the tradeoff when the tradeoff is actually managed. That’s the job: not hiding the nausea, managing it. For the full research and treatment library, see the Summit Metabolic Health blog.

Ready to start? Apply at summitmetabolichealth.com/apply.

This post is educational and does not replace individualized medical advice. Talk to a physician about your history before starting any GLP-1 medication.